You are on page 1of 20

FinancialResultsfortheFirstQuarterof

FiscalYearEndingMarch31,2018(FY2017)

TerumoCorporation
ManagingExecutiveOfficer,
ff
InvestorRelations,CorporateCommunicationDept.
KazuakiKitabatake

August 3 2017
August3,2017
OverseasDoubleDigitSalesGrowthDroveOverallGrowthBothin
SalesandProfit
(billionyen)
FY16Q1 FY17Q1 YoY% YoY%
(FXN)
NetSales
Net Sales 124.5
124 5 139.3
139 3 +12% +11%
GrossProfit 69.2(55.6%) 78.3 (56.2%) +13% +15%
SG&Aexpenses 39.7(31.9%) 46.4(33.3%) +17% +15%
R&DExpenses 8.1(6.5%) 8.5(6.1%) +5% +4%
OperatingIncome 21.4(17.2%) 23.4(16.8%) +9% +17%
(Excl.Amortization) 25.9(20.8%)
( ) 30.6(22.0%)
( ) +18% +24%
OrdinaryIncome 15.1(12.1%) 22.7(16.3%) +50%
NetIncome 10.1 (8.1%) 16.3 (11.7%) +61%

AverageExchangeRate USD108yen
USD 108 111
111yen
EUR122yen 122yen
Sales:AllbusinessesinCardiacandVascularCompanymadedoubledigitgrowth,drivingoverallgrowthinsales
Operatingincome:Salesexpansionaswellasgrossmarginimprovementcontributedtothegrowth
Operating income: Sales expansion as well as gross margin improvement contributed to the growth
Ordinaryincome:PostedFXgainof0.2BJPYinFY17Q1,whilepostedlossof5.5BJPYinFY16Q1
Netincome:Decreaseincorporatetaxrateduetoexpandedscopeoftaxeffectforinsideand
outside subsidiaries
outsidesubsidiaries

2/19
OperatingIncomeVarianceAnalysis
(billionyen)
1.3
ImpactofM&AsmadeinFY16
3.1 Price
/
O/Pexcl.amortization+1.4
erosion
i 3.5 Amortization* 2.6
Grossmargin *Figuresaboveistentative
improve sincePPAisstillinprocess.
ment by
mentby Increaseof
Increase of 0.3
cost SG&A Increase
reduction, (Increaseof ofR&D 2.6
8.1 etc salaries&
wages:2.1)
ages ) IIncreaseoff
1.5
goodwill,
etc.
(Impactof FX 23.4
M&As
M&As
G/P madein
21.4
increment FY16)
bysales
increase

FY2016Q1 FY2017Q1

3/19
NetSalesbyRegion
FY17Q1
FY17 Q1
FY16Q1

NetSales YearonYearSalesComparison
100%=139.3BJPY billionyen YoY% Comments
()FXN

GoodmomentuminCardiacandVascular
44.9 Companyalleviatedthenegativegrowthin
1% GeneralHospitalCompany.Howeveroverall
32% Japan 45.5 salesendedupbeingslightlydecreased.

27.7 +12% AllbusinessesinCardiacandVascular


All businesses in Cardiac and Vascular
Companymadedoubledigitgrowth,driving
Europe 24.7 (+12%) overallgrowthinsales.
20% NotonlydidBloodManagementCompany
41 1
41.1 +25% gainamomentumback,butallbusinessesin
Americas 32.9 (+21%) CardiacandVascularCompanyachieved
highgrowth.
30% 10.2 +22% p g
Allthreecompaniesachieveddoubledigit
China
hi growth.
8.4 (+23%)
7% AllbusinessesinCardiacandVascular
Asiaand 15.3 +18% CompanyaswellasBloodManagement
11% Oth
Others 13.0 (+15%) Companymadedoubledigitgrowth.

4/19
NetSalesbyBusinessSegment
FY17Q1
FY17 Q1
FY16Q1

NetSales YearonYearSalesComparison
100%=139.3BJPY billionyen YoY% Comments
()FXN

Agreatstartfortheacquiredproducts,
g q p ,
+24% aswellassolidorganicgrowthmade
Cardiac 79.1 (+22%) allbusinessesachievedoubledigit
57% and growth.
63 7
63.7
Vascular Inventoryadjustmentforgeneral
4% hospitalproductsatdistributors,as
((4%)) wellasconservativebuyingofpumps,
36 9
36.9
Generall
G negativelyimpacted.
Hospital 38.4 Annualizedthenegativeimpactof
26% pricedeclineforbloodcenterproducts
+4% inUS.Bloodcenterproductsand
Blood 23.3 (+3%) therapeuticapheresis systeminAsia
Manage andLatinAmericasdroveoverall
17% 22.4 growth
growth.
ment

5/19
Cardiacand :AllBusinessesMadeDoubleDigitGrowth,Achieving
Vascular IncreaseBothinSalesandProfit
(billion yen)
(billionyen)

FY16Q1 FY17 Q1 YoY% MajorTopics Impact


( ) FXN
()FXN

79.1 ImpactofFX +1.1

63 7
63.7
TIS:Continuousgoodmomentuminaccess
+24% devices +1.3
Sales (+22%) Neurovascular:Hydrogel
y g coilsandsuctioncaths
droveoverallgrowth +1.4
CV :Achieveddoubledigitgrowthmainly
overseas +1.0
IncreaseinsalesduetoM&As +9.5
20.6
+6%
Business 19.5 Achievedincreaseinprofitduetosalesexpansion
Profit
(+14%)

(31%) (26%)

6/19
General
Hospital :ContinuousImprovingTrendinProfitability
(billion yen)
(billionyen)

FY16 Q1 FY17 Q1 YoY% MajorTopics Impact


( ) FXN
()FXN ImpactofFX +0.2
Generalhospitalproducts:Inventory
adjustmentatdistributors,aswellas
4% conservativebuyingofpumps 0.6
38.4 36.9 Pharmaceuticalandnutrition:Ended
(4%)
Sales distributionofbagfordialysate 0.2
Healthcare: Downsizing accounts of blood
Healthcare:Downsizingaccountsofblood
pressuremonitor,etc. 0.3
Alliance:Timingofpurchasingordersfrom
pharmaceuticalcompaniesdifferedfrom
p p
FY16Q1 0.3

5.2 5.7
+9%
Business (+10%) Continuousimprovingtrendinprofitability
Profit
(14%) (15%)

7/19
Blood :ReturnedtoGrowthTrajectoryw/Continuous
Management ImprovingTrendinProfitability
(billion yen)
(billionyen)

FY16 Q1 FY17 Q1 YoY% MajorTopics Impact


( ) FXN
()FXN

ImpactofFX +0.2
22.4 23.3
+4%
Sales (+3%) Bloodcenterbusiness:Madedoubledigit
ggrowthinAsiaandLatinAmericas +0.6
TherapeuticApheresis:Achievedgrowth
mainlyoutsideJPN +0.4

Achievedgrowthinprofitduetothesalesexpansion
+30%
Business
B i of highly profitable therapeutic apheresis alongwith
ofhighlyprofitabletherapeuticapheresis along with
2.7 3.5 (+47%)
Profit anincreasedproductionvolumeforbloodcenter
(12%) (15%) products

8/19
MajorTopicsinFY17Q1
Newmanagementteamisinplacetoacceleratethe
Corporate
executionofMidtoLongtermGrowthStrategy

AnnouncedthecompletionofAcquisitionofBoltonMedicalfor
TAAandAAAstentgrafts(Apr)

EstablishedTISMasteryCenteratAshitaka factory
Business
to further promote and reinforce R&D in TIS (Jun)
tofurtherpromoteandreinforceR&DinTIS(Jun)

EMA(EuropeanMedicinesAgency)validatedtheMarketingAuthorization

Applicationforabiosimilar drugprefilledinPLAJEX(May)

9/19
NewProductsPipelineinFY17
Category Products Region Category Products Region

Heartlungmachine
Coronary PTCAballoon US Launched
(Re launch)
(Relaunch)
CV
JP,US&
Stent(TRI) Nextgenerationofoxygenator Global
EU
JP,US&
,
PTA b ll
PTAballoon(TRI)
(TRI) General V i li f i
Verticalinfusionpump JP
EU
Hospital
JP,US& Needlelessinfusionsystemfor JP:
Peripheral PTA guidingsheath(TRI) Products
EU Anticancerdrugs Launched

Drug coatedballoon EU DM Insulinpatchpump JP

Embolizationcoil EU Blood Newsoftwareforautomated


Global
M
Management
t bl
bloodcollectionsystem
d ll ti t
EU:
Distalprotectiondevice
Launched
Neuro US&EU:
Hydrogel coil3D Launched
JP:Q2
Radioembolization beads
Oncology EU
(Quirem)
Itemwithlargecontributiontosalesandprofit DrugCoatedBalloon HeartLungMachine InsulinPatchPump
Kanshas Relaunch
Itemwithhighlyinnovativetechnology EU Global
JP

10/19
Reference

11/19
FY17Q1NetSalesandGrowthbyRegion
(billionyen)

Business OutsideofJapan
Japan
p G.Total
S
Segmentt Subtotal Europe Americas China Asia
Cardiacand 13.5 65.6 20.1 29.1 8.5 7.9 79.1
Vascular (+5%)
(+5%) (+27%)
(+27%) (+20%)
(+20%) (+32%)
(+32%) (+26%)
(+26%) (+27%)
(+27%) (+22%)
(+22%)
OutofC&V
10.3 53.3 16.1 22.6 7.9 6.7 63.5
Interventional
S t
Systems** (+4%)
(+4%) (+28%)
(+28%) (+17%)
(+17%) (+38%)
(+38%) (+24%)
(+24%) (+30%)
(+30%) (+23%)
(+23%)

General 28.9 7.9 1.9 1.7 0.5 3.9 36.9


Hospital (4%) (6%) (12%) (6%) (+10%) (4%) (4%)
Blood
2.4 20.9 5.8 10.3 1.2 3.5 23.3
Manage
(3%) (+4%) (3%) (+4%) (+11%) (+14%) (+3%)
ment
44.9 94.4 27.7 41.1 10.2 15.3 139.3
G. Total
(1%) (+18%) (+12%) (+21%) (+23%) (+15%) (+11%)

*IncludingNeurovascularbusiness (YoY%):FXN
12/19
OperatingExpenses
(
(billionyen)
)

FY16Q1 FY17Q1 YoY YoY% YoY%


(FXN)

Salaries&Wages 17.9 20.3 +2.4 +13% +12%


SalesPromotion 3.8 4.1 +0.3 +7% +7%
LogisticalCosts 2.8 3.0 +0.2 +7% +7%
Depreciation&
Depreciation &
62
6.2 91
9.1 +2.9
29 +48%
48% +45%
45%
Amortization
Others 9.0 9.9 +0.9 +9% +8%
SG&AExpensesTotal
39.7 46.4 +6.7 +17% +15%
(31.9%) (33.3%)

R&DExpenses
81
8.1 85
8.5 +0.4 +5% +4%
(6.5%) (6.1%)

OperatingExpensesTotal
47 8
47.8 54 9
54.9 +7.1
71 +15%
15% +13%
13%
(38.4%) (39.4%)

13/19
QuarterlyResults
(
(billionyen)
)
FY16Q1 Q2 Q3 Q4 FY17Q1
((AprJun)
p ) ((JulSep)
p) ((OctDec)) ((JanMar)) ((AprJun)
p )

NetSales 124.5 120.6 129.3 139.8 139.3

G
GrossProfit
P fit 69 2
69.2 65 8
65.8 68 7
68.7 74 3
74.3 78 3
78.3
(55.6%) (54.6%) (53.2%) (53.2%) (56.2%)

SG&AExpenses 39.7 39.6 41.0 47.4 46.4


(31.9%) (32.9%) (31.7%) (34.0%) (33.3%)

R&DExpenses 8.1 8.2 8.2 9.2 8.5


(6.5%) (6.8%) (6.4%) (6.6%) (6.1%)
Operating 21.4 18.0 19.5 17.7 23.4
Income (17.2%) (14.9%) (15.1%) (12.6%) (16.8%)

(Excl. 25.9 22.6 24.5 24.2 30.6


Amortization) (20.8%) (18.8%) (19.0%) (17.4%) (22.0%)

Average USD 108 yen 102 yen 109 yen 114 yen 111 yen
Exchange
EUR 122 yen 114 yen 118 yen 121 yen 122 yen
Rate

14/19
CAPEXandR&DExpenses
(billionyen)
Amortization
Expandinvestmentin
56.0
ofIntangibles productioncapacity
aandGoodwill
d Good 45 4
45.4 46 5
46.5 and space as well as
andspaceaswellas
44 7
44.7
41.4 40.7
39.1 ITinfrastructurein
31.5 FY17
28.5
17 7
17.7 20 2
20.2 20 8
20.8

CAPEX 13.8 Amortizationof


8.9
7.2 intangiblesand
23.0 24.5 24.6 27.5 goodwillare
6.5
Depreciation CAPEX:CIPbasis projectedtoincrease
duetoM&As
41.0 madeinFY16
33.1 33.6
29.4
Further promoteUS
basedR&Dactivities
R&D 8.5*
Expenses forTISand
neurovascular
FY2014 FY2015 FY2016 FY2017Q1 FY2017
Guidance
*InvestmentintoventuretechnologieswasbookedinotherthanR&Dexpenses.(0.7BJPY)
15/19
CashFlow
OperatingCF InvestmentandFinanceCF
(billionyen)
+15.6 +3.1

8.1
13.8
Corporate
Finance
Tax
Depreci 13.5
ation and
ationand 77
7.7
amorti 0.2
zation Increaseof Repayment Dividends Others
23.4 8.9 forshort
working
capital termdebt
139 9
139.9
CAPEX
Income 124.1
before
105.4 tax
120.0

Cashatendof CAPEX=C.i.P.recordbasis Cashatendof


FY16 CashatendofeachfiscalyearisconsistentwithcashanddepositsonBS FY17Q1

16/19
FY17ForeignExchangeSensitivity
(billionyen)

USD EUR CNY


Excl. Incl.
Amortization Amortization

NetSales 1.6 1.6 0.8 1.8


Operating
Income
0.0 0.2 0.5 0.9

<Reference>Impactof+/10%fluctuation
North Latin EMEA Asia
America America EUR Others CNY Others
Operating
p g
1.8
18 08
0.8 56
5.6 10
1.0 14
1.4 33
3.3
Income
17/19
(Reference)IFRSBasis
AdoptingInternationalFinancialReportingStandards(IFRS)fromtheyear
endfinancialannouncementforFY17
Schedulefordisclosure
Schedule for disclosure
FY17Q1Q3 :JapaneseGAAP
y
FY17yearendfinancialannouncement :IFRS
Reference
JapaneseGAAP IFRS
(billionyen) Impact
FY17 Q1
FY17Q1 FY17 Q1
FY17Q1
NetSales 139.3 139.3

Operating 23 4
23.4 28 6
28.6
+5.2
Income(%) (16.8%) (20.5%)
Adjusted 30 6
30.6 31 7
31.7
Operating +1.1
Income(%) (22.0%) (22.8%)

Net Income
NetIncome 16 3
16.3 20 6
20.6 +4 3
+4.3

18/19
IRContact

TerumoCorporation
CorporateCommunication(IR)Dept.
Email:kouhou_terumo01@terumo.co.jp

AmongtheinformationthatTerumodiscloses,theforwardlookingstatementsincludingfinancial
projections are based upon our assumptions using information available to us at the time and are not
projectionsarebaseduponourassumptionsusinginformationavailabletousatthetimeandarenot
intendedtobeguaranteesoffutureeventsorperformance.Accordingly,itshouldbenotedthatactual
resultsmaydifferfromthoseforecastsonprojectionsduetovariousfactors.Factorsaffectingtoactual
resultsinclude,butarenotlimitedto,changesineconomicconditionssurroundingTerumo,fluctuations
offoreignexchangerates,andstateofcompetition.

Th
Themarketshareinformationinthispresentationispartlyderivedfromourownindependentresearch.
k h i f i i hi i i l d i df i d d h

19/19
Terumo Corporation